Gilead's anti water strategy for sovaldi was severely criticized

Source: Ding Xiangyuan 2015-04-15 the generic drug of the hepatitis C treatment drug sovaldi of Gilead began to appear on the market, and Gilead was charged with preventing patients from obtaining the drug Last year, Geely reached a series of licenses with generics companies to allow about 90 low-income countries around the world to list and sell low-cost sovaldi (sofosbuvir) generics The agreement is intended to allow generic drugs to be sold at a price of about $900 a course on Monday, which is only a small part of the price set in developed countries, but critics say the price may have to be reduced to $100 to make them truly affordable Currently, m é decins sans fronti è res (MSF), a medical charity, says Gilead's efforts to prevent the drug from being transferred or re sold from low - and middle-income countries to richer countries are tantamount to "intrusive monitoring" of patients MSF first expressed concern about last month's "anti water" program, saying Geely introduced a cumbersome and potentially harmful process aimed at protecting the company's ability to charge high prices in developed countries The charity said Gilead's plan violated patient privacy, undermined patient confidentiality, and the introduction of high-pressure and monitoring medical providers could lead to the interruption of patients' treatment, leading to treatment resistance and failure Sovaldi generics are now entering India and other countries, such as Egypt Gilead insists its efforts are merely to stop "widespread mass transfers," and denies requiring its Indian licensing company to collect all information about patients who have access to the drug MSF said the company is requiring generic drugs to be registered with the identity, nationality and residence of the patients at the time of sale The charity also expressed concern about using QR codes to mark each bottle of generic drugs, saying it would include the patient's name and address India is introducing a 2D barcode system for drug packaging to allow drug traceability and reduce the threat of counterfeiting, but it is required by law to include only a unique sequence number, GTIN, batch number and expiry date